|
mutLBSgeneDB |
| |
| |
| |
| |
| |
| |
|
| Gene summary for EPHB4 |
 Gene summary |
| Basic gene Info. | Gene symbol | EPHB4 |
| Gene name | EPH receptor B4 | |
| Synonyms | HTK|MYK1|TYRO11 | |
| Cytomap | UCSC genome browser: 7q22 | |
| Type of gene | protein-coding | |
| RefGenes | NM_004444.4, | |
| Description | ephrin receptor EphB4ephrin type-B receptor 4hepatoma transmembrane kinasesoluble EPHB4 variant 1soluble EPHB4 variant 2soluble EPHB4 variant 3tyrosine-protein kinase TYRO11tyrosine-protein kinase receptor HTK | |
| Modification date | 20141207 | |
| dbXrefs | MIM : 600011 | |
| HGNC : HGNC | ||
| Ensembl : ENSG00000196411 | ||
| HPRD : 02481 | ||
| Vega : OTTHUMG00000157040 | ||
| Protein | UniProt: P54760 go to UniProt's Cross Reference DB Table | |
| Expression | CleanEX: HS_EPHB4 | |
| BioGPS: 2050 | ||
| Pathway | NCI Pathway Interaction Database: EPHB4 | |
| KEGG: EPHB4 | ||
| REACTOME: EPHB4 | ||
| Pathway Commons: EPHB4 | ||
| Context | iHOP: EPHB4 | |
| ligand binding site mutation search in PubMed: EPHB4 | ||
| UCL Cancer Institute: EPHB4 | ||
| Assigned class in mutLBSgeneDB | B: This gene belongs to targetable_mutLBSgenes. | |
| Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez |
| GO ID | GO Term | PubMed ID | GO:0002042 | cell migration involved in sprouting angiogenesis | 12734395 | GO:0007155 | cell adhesion | 12734395 | GO:0018108 | peptidyl-tyrosine phosphorylation | 8188704 | GO:0046777 | protein autophosphorylation | 8188704 | GO:0048013 | ephrin receptor signaling pathway | 12734395 |
| Top |
| Ligand binding site mutations for EPHB4 |
| Lollipop-style diagram of mutations at LBS in amino-acid sequence. We represented ligand binding site mutations only. (You can see big image via clicking.)  : non-synonymous mutation on LBS, Circle size denotes number of samples. |
 |
| Cancer type specific mutLBS sorted by frequency |
| LBS | AAchange of nsSNV | Cancer type | # samples | D758 | D758H | BRCA | 1 | A700 | D702N | GBM | 1 | V629 | R631L | LUAD | 1 | I691 | V689I | OV | 1 | V620 | E619K | SKCM | 1 | S99 | S99F | SKCM | 1 | M668 | I667T | STAD | 1 | K647 | L649M | UCEC | 1 |
| cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma. |
| Top |
| Protein structure related information for EPHB4 |
| Relative protein structure stability change (ΔΔE) using Mupro 1.1 Mupro score denotes assessment of the effect of mutations on thermodynamic stability. (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability) |
 : nsSNV at non-LBS : nsSNV at LBS |
 |
| nsSNVs sorted by the relative stability change of protein structure by each mutation Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene. |
| LBS | AAchange of nsSNV | Relative stability change | V629 | R631L | 0.1771348 | K647 | L649M | -1.4023314 | V620 | E619K | -1.2993842 | M668 | I667T | -1.188256 | I691 | V689I | -0.76712462 | D758 | D758H | -0.5940049 | A700 | D702N | -0.51813062 | S99 | S99F | -0.33767305 |
| (MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132) |
| Structure image for EPHB4 from PDB |
| Top |
| Differential gene expression and gene-gene network for EPHB4 |
| Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types |
| Differential co-expressed gene network based on protein-protein interaction data (CePIN) |
| Top |
| Top |
| Phenotype information for EPHB4 |
| Gene level disease information (DisGeNet) |
| Disease ID | Disease name | # PubMed | Association type |
| umls:C1458155 | Breast Neoplasms | 2 | Biomarker |
| Mutation level pathogenic information (ClinVar annotation) |
| Allele ID | AA change | Clinical significance | Origin | Phenotype IDs |
| Top |
| Pharmacological information for EPHB4 |
| Gene expression profile of anticancer drug treated cell-lines (CCLE) Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient. |
 |
| Gene-centered drug-gene interaction network |
 |
| Drug information targeting mutLBSgene (Approved drugs only) |
| Drug status | DrugBank ID | Name | Type | Drug structure |
| Investigational | DB05007 | XL647 | Small molecule |  |
| Experimental | DB07249 | N-(5-chloro-1,3-benzodioxol-4-yl)-6-methoxy-7-(3-piperidin-1-ylpropoxy)quinazolin-4-amine | Small molecule |  |
| Experimental | DB07250 | N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5- TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE | Small molecule |  |
| Experimental | DB07251 | N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE | Small molecule |  |
| Experimental | DB07252 | 3-({4-[(5-chloro-1,3-benzodioxol-4-yl)amino]pyrimidin-2-yl}amino)benzenesulfonamide | Small molecule |  |
| Experimental | DB07253 | N'-(5-chloro-1,3-benzodioxol-4-yl)-N-(3-methylsulfonylphenyl)pyrimidine-2,4-diamine | Small molecule |  |
| Experimental | DB07254 | N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE | Small molecule |  |
| Experimental | DB07255 | N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-MORPHOLIN-4-YLPHENYL)PYRIMIDINE-2,4-DIAMINE | Small molecule |  |
| Experimental | DB07256 | 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE | Small molecule |  |
| Gene-centered ligand-gene interaction network |
 |
| Ligands binding to mutated ligand binding site of EPHB4 go to BioLip |
| Ligand ID | Ligand short name | Ligand long name | PDB ID | PDB name | mutLBS | MG | MAGNESIUM(2+) | 2vwx | A | D758 | MG | MAGNESIUM(2+) | 2vwx | A | D758 | MG | MAGNESIUM(2+) | 2vwy | A | D758 | MG | MAGNESIUM(2+) | 2vwy | A | D758 | MG | MAGNESIUM(2+) | 2vwz | A | D758 | MG | MAGNESIUM(2+) | 2vwz | A | D758 | MG | MAGNESIUM(2+) | 2vx0 | A | D758 | MG | MAGNESIUM(2+) | 2vx0 | A | D758 | MG | MAGNESIUM(2+) | 2vx1 | A | D758 | MG | MAGNESIUM(2+) | 2vx1 | A | D758 | MG | MAGNESIUM(2+) | 2x9f | A | D758 | MG | MAGNESIUM(2+) | 2x9f | A | D758 | MG | MAGNESIUM(2+) | 2xvd | A | D758 | MG | MAGNESIUM(2+) | 2xvd | A | D758 | MG | MAGNESIUM(2+) | 4bb4 | A | D758 | X9F | N^4^-1H-INDAZOL-4-YL-N^2^-[3-(METHYLSULFONYL)PHENYL]PYRIMIDINE-2,4-DIAMINE | 2x9f | A | K647 D758 | 7X4 | 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZENESULFONAMIDE | 2vwx | A | K647 I691 | 7X5 | N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3-METHYLSULFONYLPHENYL)PYRIMIDINE-2,4-DIAMINE | 2vwy | A | K647 I691 | 7X6 | N-[3-[[4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL]AMINO]PHENYL]METHANESULFONAMIDE | 2vwz | A | K647 I691 | 7X7 | 2,4-PYRIMIDINE DERIVATIVE | 2vx0 | A | K647 I691 | 7X8 | 3-({4-[(5-CHLORO-1,3-BENZODIOXOL-4-YL)AMINO]PYRIMIDIN-2-YL}AMINO)BENZAMIDE | 2vx1 | A | K647 I691 | 7X2 | N'-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-N-(3,4,5-TRIMETHOXYPHENYL)PYRIMIDINE-2,4-DIAMINE | 2vww | A | K647 I691 A700 | 7X1 | N-(5-CHLORO-1,3-BENZODIOXOL-4-YL)-6-METHOXY-7-(3-PIPERIDIN-1-YLPROPOXY QUINAZOLIN-4-AMINE | 2vwu | A | K647 M668 I691 | III | Peptide ligand (ASN,TYR,LEU,PHE,SER,PRO,ASN,GLY,PRO,ILE,ALA,ARG,ALA,TRP) | 2bba | A | S99 | 32W | N-(2-METHOXYETHYL)-4-[(6-PYRIDIN-4- YLQUINAZOLIN-2-YL)AMINO]BENZAMIDE | 4bb4 | A | V620 V629 K647 M668 I691 | STU | STAUROSPORINE | 3zew | B | V629 A700 D758 | 7X3 | N'-(3-CHLORO-4-METHOXY-PHENYL)-N-(3,4,5-TRIMETHOXYPHENYL)-1,3,5-TRIAZINE-2,4-DIAMINE | 2vwv | A | V629 K647 | STU | STAUROSPORINE | 2yn8 | A | V629 K647 A700 D758 | STU | STAUROSPORINE | 2yn8 | B | V629 K647 D758 | STU | STAUROSPORINE | 3zew | A | V629 K647 D758 | AS6 | {4-METHYL-3-[(1-METHYLETHYL)(2-{[3-(METHYLSULFONYL)-5-MORPHOLIN-4-YLPHENYL]AMINO}PYRIMIDIN-4-YL)AMINO]PHENYL}METHANOL | 2xvd | A | V629 K647 M668 D758 |
| Top |
| Conservation information for LBS of EPHB4 |
| Multiple alignments for P54760 in multiple species |
| LBS | AA sequence | # species | Species |
 |
Copyright © 2016-Present - The University of Texas Health Science Center at Houston |